News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

PHARNEXT Receives Clinical Trial Authorization for a Phase II Study with the First Drug Generated by Its Pleotherapy(TM) Technology


12/3/2010 8:50:25 AM

PARIS--(BUSINESS WIRE)--Pharnext SAS, a biopharmaceutical company specializing in the development of innovative treatments for severe neurological diseases and other major unmet medical needs, today announced that the French Agency for Healthcare Product Safety (AFSSAPS) has authorized a Phase II clinical trial with the first drug (a Pleodrug™) generated by the company's Pleotherapy™ technology platform in patients suffering from Charcot-Marie Tooth disease type 1A (CMT1A) - a chronic, severe, invalidating and currently incurable neuromuscular disease which affects 3 million people worldwide.

Read at BioSpace.com

comments powered by Disqus
PHARNEXT
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES